Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT1A weak partial agonistic activity showing the antidepressant-like effect

  • Bioorg Med Chem. 2017 Jan 1;25(1):293-304. doi: 10.1016/j.bmc.2016.10.034.
Hidefumi Yoshinaga  1 Shuji Masumoto  2 Koji Koyama  2 Naoya Kinomura  2 Yuji Matsumoto  2 Taro Kato  2 Satoko Baba  2 Kenji Matsumoto  2 Tomoko Horisawa  2 Hitomi Oki  2 Kazuki Yabuuchi  2 Toru Kodo  2
Affiliations
  • 1. Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan. Electronic address: [email protected].
  • 2. Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., 33-94 Enoki-cho, Suita, Osaka 564-0053, Japan.
Abstract

We report the discovery of a novel benzylpiperidine derivative with Serotonin Transporter (SERT) inhibitory activity and 5-HT1A receptor weak partial agonistic activity showing the antidepressant-like effect. The 3-methoxyphenyl group and the phenethyl group of compound 1, which has weak SERT binding activity, but potent 5-HT1A binding activity, were optimized, leading to compound 35 with potent and balanced dual SERT and 5-HT1A binding activity, but also potent CYP2D6 inhibitory activity. Replacement of the methoxy group in the left part of compound 35 with a larger alkoxy group, such as ethoxy, isopropoxy or methoxy-ethoxy group ameliorated CYP2D6 inhibition, giving SMP-304 as a candidate. SMP-304 with serotonin uptake inhibitory activity and 5-HT1A weak partial agonistic activity, which could work as a 5-HT1A antagonist, displayed faster onset of antidepressant-like effect than a representative SSRI paroxetine in an animal model.

Keywords
5-HT(1A) receptor; Antidepressant; Benzylpiperidine; Fast onset; Serotonin transporter.